12:00 AM
Jul 29, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

LOR-253: Phase I data

An open-label, dose-escalation, U.S. Phase I trial in 27 patients with advanced or metastatic solid tumors who previously failed a median of 4 prior chemotherapies showed that 20-229 mg/m 2 doses of LOR-253 were well tolerated. The most common adverse event...

Read the full 185 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >